178 related articles for article (PubMed ID: 371651)
1. The metabolism of [14C]-debrisoquine in man.
Idle JR; Mahgoub A; Angelo MM; Dring LG; Lancaster R; Smith RL
Br J Clin Pharmacol; 1979 Mar; 7(3):257-66. PubMed ID: 371651
[TBL] [Abstract][Full Text] [Related]
2. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
3. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
Allen JG; East PB; Francis RJ; Haigh JL
Drug Metab Dispos; 1975; 3(5):332-7. PubMed ID: 241613
[TBL] [Abstract][Full Text] [Related]
5. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.
Meese CO; Fischer C; Eichelbaum M
Biomed Environ Mass Spectrom; 1988 Jan; 15(2):63-6. PubMed ID: 3349209
[TBL] [Abstract][Full Text] [Related]
6. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.
Lennard MS; Silas JH; Smith AJ; Tucker GT
J Chromatogr; 1977 Mar; 133(1):161-6. PubMed ID: 838796
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
[TBL] [Abstract][Full Text] [Related]
8. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
10. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
13. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
Nordin C; Siwers B; Benitez J; Bertilsson L
Br J Clin Pharmacol; 1985 Jun; 19(6):832-5. PubMed ID: 4027124
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of debrisoquine sulphate in rat, dog and man.
Allen JG; Brown AN; Marten TR
Xenobiotica; 1976 Jul; 6(7):405-9. PubMed ID: 997588
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
17. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Al-Dabbagh SG; Idle JR; Smith RL
J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
[TBL] [Abstract][Full Text] [Related]
18. Why hypertensive patients vary in their response to oral debrisoquine.
Silas JH; Lennard MS; Tucker GT; Smith AJ; Malcolm SL; Marten TR
Br Med J; 1977 Feb; 1(6058):422-5. PubMed ID: 837136
[TBL] [Abstract][Full Text] [Related]
19. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
20. The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method.
Kallio J
Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):223-6. PubMed ID: 2163994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
